Lansoprazole-d4
(Synonyms: 兰索拉唑-D4,AG-1749-d4) 目录号 : GC47537
An internal standard for the quantification of lansoprazole
Cas No.:934294-22-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Lansoprazole-d4 is intended for use as an internal standard for the quantification of lansoprazole by GC- or LC-MS. Lansoprazole is a proton pump inhibitor that inhibits the H+/K+-ATPase.1 It inhibits K+ and H+ accumulation in gastric microsomes in a concentration-dependent manner (IC50s = 6.3 and 7 µM, respectively) and inhibits H+/K+-ATPase activity by approximately 60% when used at a concentration of 10 µM. Lansoprazole inhibits the H+/K+-ATPase in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH.2 It is a substituted benzimidazole that binds covalently to proton pumps, providing complete and prolonged inhibition of acid secretion.3,4 Formulations containing lansoprazole have been used as a proton pump inhibitor and in combination with antibiotics in the treatment of H. pylori infections and duodenal ulcer disease.
1.Nagaya, H., Satoh, H., Kubo, K., et al.Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749J. Pharmacol. Exp. Ther.248(2)799-805(1989) 2.Schubert, M.L.Pharmacotherapy for acid/peptic disordersYale J. Biol. Med.69(2)197-201(1996) 3.Richardson, P., Hawkey, C.J., and Stack, W.A.Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disordersDrugs56(3)307-335(1998) 4.Klotz, U.Pharmacokinetic considerations in the eradication of Helicobacter pyloriClin. Pharmacokinet.38(3)243-270(2000)
| Cas No. | 934294-22-1 | SDF | |
| 别名 | 兰索拉唑-D4,AG-1749-d4 | ||
| Canonical SMILES | CC1=C(CS(C2=NC(C([2H])=C([2H])C([2H])=C3[2H])=C3N2)=O)N=CC=C1OCC(F)(F)F | ||
| 分子式 | C16H10D4F3N3O2S | 分子量 | 373.4 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6781 mL | 13.3905 mL | 26.7809 mL |
| 5 mM | 0.5356 mL | 2.6781 mL | 5.3562 mL |
| 10 mM | 0.2678 mL | 1.339 mL | 2.6781 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。